Search

Your search keyword '"Schneider-Futschik, Elena K."' showing total 152 results
Start Over Author "Schneider-Futschik, Elena K."
152 results on '"Schneider-Futschik, Elena K."'

2. Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline

Author

Khatri, Sumita B, Iaccarino, Jonathan M, Barochia, Amisha, Soghier, Israa, Akuthota, Praveen, Brady, Anna, Covar, Ronina A, Debley, Jason S, Diamant, Zuzana, Fitzpatrick, Anne M, Kaminsky, David A, Kenyon, Nicholas J, Khurana, Sandhya, Lipworth, Brian J, McCarthy, Kevin, Peters, Michael, Que, Loretta G, Ross, Kristie R, Schneider-Futschik, Elena K, Sorkness, Christine A, and Hallstrand, Teal S

Subjects
Lung, Clinical Trials and Supportive Activities, Clinical Research, Asthma, 7.3 Management and decision making, Management of diseases and conditions, Respiratory, Adrenal Cortex Hormones, Anti-Asthmatic Agents, Humans, Nitric Oxide, Practice Guidelines as Topic, United States, nitric oxide, asthma, inhaled steroids, airway disease, type 2 inflammation, American Thoracic Society Assembly on Allergy, Immunology, and Inflammation, Medical and Health Sciences, Respiratory System
Abstract

Background: The fractional exhaled nitric oxide (FENO) test is a point-of-care test that is used in the assessment of asthma. Objective: To provide evidence-based clinical guidance on whether FENO testing is indicated to optimize asthma treatment in patients with asthma in whom treatment is being considered. Methods: An international, multidisciplinary panel of experts was convened to form a consensus document regarding a single question relevant to the use of FENO. The question was selected from three potential questions based on the greatest perceived impact on clinical practice and the unmet need for evidence-based answers related to this question. The panel performed systematic reviews of published randomized controlled trials between 2004 and 2019 and followed the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) evidence-to-decision framework to develop recommendations. All panel members evaluated and approved the recommendations. Main Results: After considering the overall low quality of the evidence, the panel made a conditional recommendation for FENO-based care. In patients with asthma in whom treatment is being considered, we suggest that FENO is beneficial and should be used in addition to usual care. This judgment is based on a balance of effects that probably favors the intervention; the moderate costs and availability of resources, which probably favors the intervention; and the perceived acceptability and feasibility of the intervention in daily practice. Conclusions: Clinicians should consider this recommendation to measure FENO in patients with asthma in whom treatment is being considered based on current best available evidence.

Published
2021

5. Game changers in science and technology - now and beyond

Author

Betz, Ulrich A.K., Arora, Loukik, Assal, Reem A., Azevedo, Hatylas, Baldwin, Jeremy, Becker, Michael S., Bostock, Stefan, Cheng, Vinton, Egle, Tobias, Ferrari, Nicola, Schneider-Futschik, Elena K., Gerhardy, Stefan, Hammes, Alexandra, Harzheim, Achim, Herget, Thomas, Jauset, Cristina, Kretschmer, Simon, Lammie, Corey, Kloss, Nina, Fernandes, Steve Marquis, Mitrofan, Claudia-Gabriela, Myrgorodska, Iuliia, Nedbalek, Daniela, Neumann, Siegfried G., Paffenholz, Stella, Ponce, Laia Pascual, Rogell, Birgit, Savic, Dragana, Velikova, Gergana, Schumacher, Christian, Weisshaar, Nina, Yahya, Mohammadzadeh, Yang, Joshua Y.C., and Zhao, Guoping

Published
2023
Full Text
View/download PDF

11. Predictive factors for lumacaftor/ivacaftor clinical response

Author

Masson, Alexandra, Schneider-Futschik, Elena K., Baatallah, Nesrine, Nguyen-Khoa, Thao, Girodon, Emmanuelle, Hatton, Aurélie, Flament, Thomas, Le Bourgeois, Muriel, Chedevergne, Frederique, Bailly, Céline, Kyrilli, Sylvia, Achimastos, Diane, Hinzpeter, Alexandre, Edelman, Aleksander, and Sermet-Gaudelus, Isabelle

Published
2019
Full Text
View/download PDF

16. Ocular development after highly effective modulator treatment early in life.

Author

Yimin Zhu, Danni Li, Reyes-Ortega, Felisa, Chinnery, Holly R., and Schneider-Futschik, Elena K.

Subjects
BREASTFEEDING, CYSTIC fibrosis, CYSTIC fibrosis transmembrane conductance regulator, BREAST milk, QUALITY of life, CATARACT
Abstract

Highly effective cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator therapies (HEMT), including elexacaftor-tezacaftor-ivacaftor, correct the underlying molecular defect causing CF. HEMT decreases general symptom burden by improving clinical metrics and quality of life for most people with CF (PwCF) with eligible CFTR variants. This has resulted in more pregnancies in women living with CF. All HEMT are known to be able pass through the placenta and into breast milk in mothers who continue on this therapy while pregnant and breast feeding. Toxicity studies of HEMT in young rats demonstrated infant cataracts, and case reports have reported the presence of congenital cataracts in early life exposure to HEMT. This article reviews the evidence for how HEMT influences the dynamic and interdependent processes of healthy and abnormal lens development in the context of HEMT exposure during pregnancy and breastfeeding, and raises questions that remain unanswered. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Gastrointestinal consequences of lipopolysaccharide-induced lung inflammation

Author

McQuade, Rachel M., primary, Bandara, Methma, additional, Diwakarla, Shanti, additional, Sahakian, Lauren, additional, Han, Myat Noe, additional, Al Thaalibi, Maryam, additional, Di Natale, Madeleine R., additional, Tan, Marsha, additional, Harwood, Kiera H., additional, Schneider-Futschik, Elena K., additional, and Jarnicki, Andrew, additional

Published
2022
Full Text
View/download PDF

22. Pulmonary function testing during SARS‐CoV ‐2: An ANZSRS / TSANZ position statement

Author

Borg, Brigitte M., primary, Osadnik, Christian, additional, Adam, Keith, additional, Chapman, David G., additional, Farrow, Catherine E., additional, Glavas, Vanda, additional, Hancock, Kerry, additional, Lanteri, Celia J., additional, Morris, Ewan G., additional, Romeo, Nicholas, additional, Schneider‐Futschik, Elena K., additional, and Selvadurai, Hiran, additional

Published
2022
Full Text
View/download PDF

25. Advantages and Disadvantages of Using Magnetic Nanoparticles for the Treatment of Complicated Ocular Disorders

Author

Schneider-Futschik, Elena K., Reyes-Ortega, Felisa, [Schneider-Futschik,EK] Department of Biochemistry & Pharmacology, Faculty of Medicine, School of Biomedical Sciences, Dentistry and Health Sciences, The University of Melbourne, Parkville, Australia. [Reyes-Ortega,F] Visual Quality Research Group, Department of Ophthalmology, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofía University Hospital and University of Cordoba, Cordoba, Spain., and This work was funded from Plan Andaluz de Investigación, Desarrollo e Innovación (PAIDI2020) Fellowship supported by Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía co-funded by Fondo Social Europeo de Andalucía 2014–2020. Portions of this work were supported by the NHMRC Fellowship Scheme (APP1157287).

Subjects
Therapeutic agents, Usos terapéuticos, Diseases::Digestive System Diseases::Pancreatic Diseases::Cystic Fibrosis [Medical Subject Headings], Diseases::Eye Diseases [Medical Subject Headings], Diagnóstico, Magnetoterapia, Nanopartículas magnéticas de óxido de hierro, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Magnetic Resonance Imaging [Medical Subject Headings], Magnetic diagnosis agents, Ocular cancer, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Hyperthermia, Induced [Medical Subject Headings], Cystic fibrosis, Chemicals and Drugs::Pharmaceutical Preparations::Dosage Forms::Drug Carriers [Medical Subject Headings], Fibrosis quística, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Chemicals and Drugs::Inorganic Chemicals::Iron Compounds::Ferric Compounds::Ferrosoferric Oxide::Magnetite Nanoparticles [Medical Subject Headings], Phenomena and Processes::Physical Phenomena::Magnetic Phenomena::Magnetic Fields [Medical Subject Headings], Anthropology, Education, Sociology and Social Phenomena::Social Sciences::Anthropology::Anthropology, Cultural::Culture::Human Body [Medical Subject Headings], Magnetic nanoparticles, Ocular disorders, Oftalmopatías, Neoplasias del ojo
Abstract

Nanomaterials provide enormous opportunities to overcome the limitations of conventional ocular delivery systems, such as low therapeutic efficacy, side effects due to the systemic exposure, or invasive surgery. Apart from the more common ocular disorders, there are some genetic diseases, such as cystic fibrosis, that develop ocular disorders as secondary effects as long as the disease progresses. These patients are more difficult to be pharmacologically treated using conventional drug routes (topically, systemic), since specific pharmacological formulations can be incompatible, display increased toxicity, or their therapeutic efficacy decreases with the administration of different kind of chemical molecules. Magnetic nanoparticles can be used as potent drug carriers and magnetic hyperthermia agents due to their response to an external magnetic field. Drugs can be concentrated in the target point, limiting the damage to other tissues. The other advantage of these magnetic nanoparticles is that they can act as magnetic resonance imaging agents, allowing the detection of the exact location of the disease. However, there are some drawbacks related to their use in drug delivery, such as the limitation to maintain efficacy in the target organ once the magnetic field is removed from outside. Another disadvantage is the difficulty in maintaining the therapeutic action in three dimensions inside the human body. This review summarizes all the application possibilities related to magnetic nanoparticles in ocular diseases. Yes

Published
2021

27. Pulmonary function testing during SARS‐CoV‐2: An ANZSRS/TSANZ position statement.

Author

Borg, Brigitte M., Osadnik, Christian, Adam, Keith, Chapman, David G., Farrow, Catherine E., Glavas, Vanda, Hancock, Kerry, Lanteri, Celia J., Morris, Ewan G., Romeo, Nicholas, Schneider‐Futschik, Elena K., and Selvadurai, Hiran

Subjects
PULMONARY function tests, COVID-19 testing, COVID-19, MEDICAL personnel, INFECTION prevention
Abstract

The Thoracic Society of Australia and New Zealand (TSANZ) and the Australian and New Zealand Society of Respiratory Science (ANZSRS) commissioned a joint position paper on pulmonary function testing during coronavirus disease 2019 (COVID‐19) in July 2021. A working group was formed via an expression of interest to members of both organizations and commenced work in September 2021. A rapid review of the literature was undertaken, with a 'best evidence synthesis' approach taken to answer the research questions formed. This allowed the working group to accept findings of prior relevant reviews or societal document where appropriate. The advice provided is for providers of pulmonary function tests across all settings. The advice is intended to supplement local infection prevention and state, territory or national directives. The working group's key messages reflect a precautionary approach to protect the safety of both healthcare workers (HCWs) and patients in a rapidly changing environment. The decision on strategies employed may vary depending on local transmission and practice environment. The advice is likely to require review as evidence grows and the COVID‐19 pandemic evolves. While this position statement was contextualized specifically to the COVID‐19 pandemic, the working group strongly advocates that any changes to clinical/laboratory practice, made in the interest of optimizing the safety and well‐being of HCWs and patients involved in pulmonary function testing, are carefully considered in light of their potential for ongoing use to reduce transmission of other droplet and/or aerosol borne diseases. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. Acinetobacter baumannii: Polymyxins Bind to the Cell Surface of Unculturable Acinetobacter baumannii and Cause Unique Dependent Resistance (Adv. Sci. 15/2020)

Author

Zhu, Yan, primary, Lu, Jing, additional, Han, Mei‐Ling, additional, Jiang, Xukai, additional, Azad, Mohammad A. K., additional, Patil, Nitin A., additional, Lin, Yu‐Wei, additional, Zhao, Jinxin, additional, Hu, Yang, additional, Yu, Heidi H., additional, Chen, Ke, additional, Boyce, John D., additional, Dunstan, Rhys A., additional, Lithgow, Trevor, additional, Barlow, Christopher K., additional, Li, Weifeng, additional, Schneider‐Futschik, Elena K., additional, Wang, Jiping, additional, Gong, Bin, additional, Sommer, Bjorn, additional, Creek, Darren J., additional, Fu, Jing, additional, Wang, Lushan, additional, Schreiber, Falk, additional, Velkov, Tony, additional, and Li, Jian, additional

Published
2020
Full Text
View/download PDF

36. Polymyxins Bind to the Cell Surface of Unculturable Acinetobacter baumannii and Cause Unique Dependent Resistance

Author

Zhu, Yan, primary, Lu, Jing, additional, Han, Mei‐Ling, additional, Jiang, Xukai, additional, Azad, Mohammad A. K., additional, Patil, Nitin A., additional, Lin, Yu‐Wei, additional, Zhao, Jinxin, additional, Hu, Yang, additional, Yu, Heidi H., additional, Chen, Ke, additional, Boyce, John D., additional, Dunstan, Rhys A., additional, Lithgow, Trevor, additional, Barlow, Christopher K., additional, Li, Weifeng, additional, Schneider‐Futschik, Elena K., additional, Wang, Jiping, additional, Gong, Bin, additional, Sommer, Bjorn, additional, Creek, Darren J., additional, Fu, Jing, additional, Wang, Lushan, additional, Schreiber, Falk, additional, Velkov, Tony, additional, and Li, Jian, additional

Published
2020
Full Text
View/download PDF

38. Effective Strategy Targeting Polymyxin-Resistant Gram-Negative Pathogens: Polymyxin B in Combination with the Selective Serotonin Reuptake Inhibitor Sertraline

Author

Hussein, Maytham, primary, Schneider-Futschik, Elena K., additional, Paulin, Olivia K. A., additional, Allobawi, Rafah, additional, Crawford, Simon, additional, Zhou, Qi Tony, additional, Hanif, Adil, additional, Baker, Mark, additional, Zhu, Yan, additional, Li, Jian, additional, and Velkov, Tony, additional

Published
2020
Full Text
View/download PDF

41. Synthesis and structure−activity relationships of teixobactin

Author

Karas, John A., primary, Chen, Fan, additional, Schneider‐Futschik, Elena K., additional, Kang, Zhisen, additional, Hussein, Maytham, additional, Swarbrick, James, additional, Hoyer, Daniel, additional, Giltrap, Andrew M., additional, Payne, Richard J., additional, Li, Jian, additional, and Velkov, Tony, additional

Published
2019
Full Text
View/download PDF

45. Synthesis and structure−activity relationships of teixobactin.

Author

Karas, John A., Chen, Fan, Schneider‐Futschik, Elena K., Kang, Zhisen, Hussein, Maytham, Swarbrick, James, Hoyer, Daniel, Giltrap, Andrew M., Payne, Richard J., Li, Jian, and Velkov, Tony

Subjects
STRUCTURE-activity relationships, METHICILLIN-resistant staphylococcus aureus, SOIL microbiology, BIOCHEMICAL mechanism of action, BACTERIAL diseases, COLISTIN
Abstract

The discovery of antibiotics has led to the effective treatment of bacterial infections that were otherwise fatal and has had a transformative effect on modern medicine. Teixobactin is an unusual depsipeptide natural product that was recently discovered from a previously unculturable soil bacterium and found to possess potent antibacterial activity against several Gram positive pathogens, including methicillin‐resistant Staphylococcus aureus and vancomycin‐resistant Enterococci. One of the key features of teixobactin as an antibiotic lead is that resistance could not be generated in a laboratory setting. This is proposed to be a result of a mechanism of action that involves binding to essential cell wall synthesis building blocks, lipid II and lipid III. Since the initial isolation report in 2015, significant efforts have been made to understand its unique mechanism of action, develop efficient synthetic routes for its production, and thus enable the generation of analogues for structure−activity relationship studies and optimization of its pharmacological properties. Our review provides a comprehensive treatise on the progress in understanding teixobactin chemistry, structure−activity relationships, and mechanisms of antibacterial activity. Teixobactin represents an exciting starting point for the development of new antibiotics that can be used to combat multidrug‐resistant bacterial ("superbug") infections. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

50. Mechanistic Insights From Global Metabolomics Studies into Synergistic Bactericidal Effect of a Polymyxin B Combination With Tamoxifen Against Cystic Fibrosis MDR Pseudomonas aeruginosa

Author

Hussein, Maytham, primary, Han, Mei-Ling, additional, Zhu, Yan, additional, Schneider-Futschik, Elena K., additional, Hu, Xiaohan, additional, Zhou, Qi Tony, additional, Lin, Yu-Wei, additional, Anderson, Dovile, additional, Creek, Darren J., additional, Hoyer, Daniel, additional, Li, Jian, additional, and Velkov, Tony, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results